poisar

Stocks · News reference

Oncolytics Biotech Receives FDA Feedback On Design Of Potential Pivotal Part B Expansion Of REO 033, Its Ongoing Randomized Study Evaluating Pelareorep In Metastatic Colorectal Cancer; Company Believes Responses Represent Important Alignment Regarding Proposed Pivotal Study Design

Aug 18, 2026, 1:03 PMBenzinga Newsdesk

Company received written feedback from the U.S. Food and Drug Administration ("FDA") regarding the design of a potential pivotal Part B expansion of REO 033, the Company’s ongoing randomized study evaluating

Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

ONCY
Source
benzinga
Observed
Aug 18, 2026, 1:03 PM
Checked
Aug 18, 2026, 1:03 PM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading